Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
6.70
+0.03 (0.45%)
At close: Mar 28, 2025, 4:00 PM
6.72
+0.02 (0.30%)
After-hours: Mar 28, 2025, 7:29 PM EDT
Vir Biotechnology Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Vir Biotechnology stock have an average target of 35.67, with a low estimate of 14 and a high estimate of 110. The average target predicts an increase of 432.39% from the current stock price of 6.70.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Vir Biotechnology stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 3 | 3 | 3 |
| Hold | 3 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $26 → $31 | Buy | Maintains | $26 → $31 | +362.69% | Feb 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $110 | Strong Buy | Reiterates | $110 | +1,541.79% | Feb 28, 2025 |
| Needham | Needham | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +183.58% | Feb 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $110 | Strong Buy | Reiterates | $110 | +1,541.79% | Jan 31, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $18 → $20 | Buy | Maintains | $18 → $20 | +198.51% | Jan 13, 2025 |
Financial Forecast
Revenue This Year
27.30M
from 74.21M
Decreased by -63.21%
Revenue Next Year
32.13M
from 27.30M
Increased by 17.69%
EPS This Year
-3.75
from -3.83
EPS Next Year
-3.56
from -3.75
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 111.5M | 95.1M | 158.8M | ||
| Avg | 27.3M | 32.1M | 60.3M | ||
| Low | n/a | 4.9M | 11.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 50.3% | 248.4% | 394.1% | ||
| Avg | -63.2% | 17.7% | 87.5% | ||
| Low | - | -82.1% | -63.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.73 | -2.56 | -2.94 | ||
| Avg | -3.75 | -3.56 | -3.31 | ||
| Low | -5.17 | -5.62 | -3.79 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.